Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2015-12-20 M&A Activity
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
关于提供信息真实性、准确性和完整性的承诺函
M&A Activity Classification · 95% confidence The document consists of multiple commitment letters from various parties involved in a transaction where Fuan Pharmaceutical (Group) Co., Ltd. plans to acquire 100% equity of Yantai Zhichu Pharmaceutical Co., Ltd. The letters are assurances regarding the truthfulness, accuracy, and completeness of information provided in relation to this acquisition transaction. There are no financial statements, no detailed financial analysis, no voting results, no management discussion, no earnings data, and no presentation materials. The document is essentially a set of legal commitment letters related to a merger/acquisition transaction. This type of document does not fit into categories like 10-K, IR, ER, or MDA. It is not a proxy statement or voting result. It is not a regulatory filing in the sense of officer certifications or compliance filings, but rather a legal commitment related to a transaction. The best fitting category is M&A Activity (TAR) because it relates to announcements and documents related to merger proposals or takeover bids, and these commitment letters are part of the transaction documentation. The document length is about 4805 characters, which is sufficient to be the document itself, not just an announcement. Therefore, the classification is TAR with high confidence.
2015-12-20 Chinese
简式权益变动报告（一）
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告" which translates to a "Simplified Equity Change Report". It details changes in shareholding by specific entities (山东只楚集团有限公司 and 烟台市电缆厂) in 福安药业（集团）股份有限公司. The document includes detailed information about the shareholding changes, the purpose and plan of the equity change, the method of equity change, approval procedures, and restrictions on share transfer. It references relevant Chinese securities laws and regulations, and includes declarations by the information disclosure obligors. The document is a formal report of changes in major shareholding stakes, including share issuance and acquisition details, and is not an announcement of a report publication, nor a full annual or interim report, nor a proxy or voting result. It fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2015-12-20 Chinese
独立董事关于公司第三届董事会第二次会议的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on a company's major asset restructuring and related transactions, including issuance of shares and cash payment for acquisition, as well as compliance with relevant laws and regulations. It references the company's board meeting and approval process, evaluation of the transaction's fairness, and regulatory approvals needed. The content focuses on the board/management's review and approval of a significant corporate transaction rather than the full audit or financial report. The document length is short (1644 characters) and it is a formal opinion related to board decisions on a major asset restructuring, which fits best under Board/Management Information (MANG). It is not a full audit report, annual report, or regulatory filing, nor is it a simple announcement or certification. Therefore, the classification is MANG with high confidence.
2015-12-20 Chinese
第三届监事会第二次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at a supervisory board meeting regarding a major asset acquisition and related financing activities. It includes specifics about the issuance of shares, cash payments, pricing, share lock-up periods, performance commitments, and related party transactions. The content focuses on the approval and details of a capital raising and asset purchase transaction, including issuance of shares and fundraising from specific investors. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document is not a full financial report, audit report, or earnings release, but a detailed announcement of a financing and acquisition transaction approved by the board and supervisory committee. Therefore, the correct classification is CAP.
2015-12-20 Chinese
审计报告
Audit Report / Information Classification · 95% confidence The document is titled '审计报告' which translates to 'Audit Report'. It includes detailed audit opinions, responsibilities of management and auditors, and extensive notes on accounting policies, financial statement preparation, and financial data for multiple years (2013, 2014, 2015). The content includes detailed financial statement notes and explanations of accounting treatments, which are typical of a standalone audit report rather than a full annual report or other filing types. The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement. There is no indication that this is a certification letter or a regulatory announcement. Therefore, the document fits the category of an Audit Report / Information (AR). 9M 2015
2015-12-20 Chinese
东莞证券股份有限公司关于公司本次资产重组前12个月内上市公司购买、出售资产的核查意见
Audit Report / Information Classification · 95% confidence The document is an independent financial advisor's verification opinion regarding the company's asset transactions in the 12 months prior to a major asset restructuring. It references regulatory frameworks related to major asset restructuring and details specific asset purchases and approvals by the China Securities Regulatory Commission (CSRC). The document is focused on verifying and confirming the absence of other major asset transactions and the independence of the current transaction from previous ones. It does not contain full financial statements or comprehensive financial performance data, nor is it a simple announcement of a report. It is a specialized audit or verification report related to asset transactions and compliance with regulatory requirements for a major asset restructuring. Therefore, it fits best under Audit Report / Information (AR). The document length is short (1691 characters), but it contains substantive verification content rather than just an announcement or certification letter, so it is not RPA or RNS. FY 2015
2015-12-20 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.